Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
07:42pm, Thursday, 29'th May 2025
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive V
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Thursday, 29'th May 2025
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck, Daiichi withdraw US application for 'guided missile' cancer drug
07:14am, Thursday, 29'th May 2025
Merck and Japan-based Daiichi Sankyo said on Thursday they have withdrawn the U.S. application for an experimental lung cancer treatment, which belongs to a lucrative class of cancer therapies that wo
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as M
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
04:10pm, Tuesday, 27'th May 2025
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treat
Merck Proves Why It's Still A Top Pharma Pick
03:46pm, Tuesday, 27'th May 2025
Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performa
Merck Announces Third-Quarter 2025 Dividend
01:24pm, Tuesday, 27'th May 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2025 Dividend.
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?
12:06pm, Monday, 26'th May 2025
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.
Should You Buy MRK Stock At $80?
12:00pm, Monday, 26'th May 2025
Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors
Merck: Defensive Yield Meets Long-Term Optionality
11:05am, Friday, 23'rd May 2025
The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
05:43pm, Thursday, 22'nd May 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society
Merck: Undervalued In Light Of Key Risks
12:30pm, Thursday, 22'nd May 2025
Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
08:15am, Thursday, 22'nd May 2025
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
06:45am, Thursday, 22'nd May 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, or
